−2.93USD
−284.23 MUSD
147.75 MUSD
91.83 M
About FibroGen, Inc
Sector
CEO
Thane Wettig
Headquarters
San Francisco
Website
Employees (FY)
486
Founded
1993
ISIN
US31572Q8087
FIGI
BBG000FW5ZL6
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of FGEN is 1.17 USD — it has decreased by 7.87% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange FibroGen, Inc stocks are traded under the ticker FGEN.
FibroGen, Inc is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
FGEN stock is 13.16% volatile and has beta coefficient of 3.50. Check out the list of the most volatile stocks — is FibroGen, Inc there?
One year price forecast for FibroGen, Inc has a max estimate of 1.50 USD and a min estimate of 1.50 USD.
FGEN earnings for the last quarter are −0.65 USD whereas the estimation was −0.68 USD which accounts for 4.56% surprise. Estimated earnings for the next quarter are −0.43 USD. See more details about FibroGen, Inc earnings.
FibroGen, Inc revenue for the last quarter amounts to 40.13 M USD despite the estimated figure of 36.84 M USD. In the next quarter revenue is expected to reach 38.90 M USD.
Yes, you can track FibroGen, Inc financials in yearly and quarterly reports right on TradingView.
FGEN stock has fallen by 19.31% compared to the previous week, the month change is a 45.58% fall, over the last year FibroGen, Inc has showed a 94.18% decrease.
FGEN net income for the last quarter is −56.23 M USD, while the quarter before that showed −63.62 M USD of net income which accounts for 11.61% change. Track more FibroGen, Inc financial stats to get the full picture.
Today FibroGen, Inc has the market capitalization of 125.44 M, it has decreased by 24.54% over the last week.
No, FGEN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, FGEN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade FibroGen, Inc stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 486.00 employees. See our rating of the largest employees — is FibroGen, Inc on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So FibroGen, Inc technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating FibroGen, Inc stock shows the sell signal. See more of FibroGen, Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on FibroGen, Inc future price: according to them, FGEN price has a max estimate of 1.50 USD and a min estimate of 1.50 USD. Read a more detailed FibroGen, Inc forecast: see what analysts think of FibroGen, Inc and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. FibroGen, Inc EBITDA is −259.28 M USD, and current EBITDA margin is −175.48%. See more stats in FibroGen, Inc financial statements.